Workflow
NSWRC(600165)
icon
Search documents
宁科生物(600165) - 2017 Q2 - 季度财报
2017-08-29 16:00
Financial Performance - The company's operating revenue for the first half of 2017 was ¥563,997,109.67, a decrease of 64.60% compared to ¥1,593,397,257.60 in the same period last year[20] - The net profit attributable to shareholders of the listed company was -¥12,077,747.10, showing an improvement of ¥41,343,600 compared to -¥53,421,339.49 in the previous year[20] - The net cash flow from operating activities was -¥35,325,245.55, compared to -¥41,927,809.82 in the same period last year[20] - The company's overall revenue for the reporting period was CNY 56,399.71 million, with a year-on-year decrease of 64.60%[40] - The company reported a net profit of CNY -1,207.77 million, which reflects a year-on-year improvement in loss by CNY 4,134.36 million[38] - The total comprehensive income for the current period is -¥22,064,411.61, compared to -¥61,080,993.88 in the previous period[113] - The total comprehensive income for the period was -192,020,695.40 RMB, compared to 4,221,093.73 RMB in the previous period, indicating a significant decline[126] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,409,683,893.96, an increase of 1.91% from ¥3,345,941,916.75 at the end of the previous year[20] - The total current assets amount to 1,513,985,155.38 RMB, slightly down from 1,535,187,050.25 RMB at the beginning of the period[101] - Total liabilities decreased slightly to CNY 2,428,081,284.03 from CNY 2,443,278,268.66, a reduction of about 0.6%[102] - The company's equity attributable to shareholders decreased to CNY 784,290,814.48 from CNY 796,752,248.80, a decline of approximately 1.6%[103] - The total amount of shareholder contributions was 34,230,545.63 RMB, reflecting the company's efforts to bolster its equity base[126] - The total owner's equity decreased by 200,068,903.87 RMB, reflecting the impact of operational challenges on financial stability[134] Revenue and Expenses - The basic earnings per share for the first half of 2017 was -¥0.018, compared to -¥0.078 in the same period last year[21] - The company's gross profit margin in the chemical raw materials and chemical products manufacturing segment increased by 3.27 percentage points[37] - The company’s sales expenses rose by 34.73% to CNY 59,899.85 million, driven by increased sales personnel commissions and transportation costs[40] - Total operating costs for the current period are ¥590,612,936.96, down 64.6% from ¥1,665,889,807.45 in the previous period[109] - Management expenses decreased to ¥34,393,457.88 from ¥38,855,676.14, a reduction of 11.9%[109] Investments and Acquisitions - The company purchased a 51% stake in San Shi Company for CNY 91.03 million, which is involved in financing leasing business[50] - The company’s long-term receivables increased by 650.20% to CNY 106,385.15 million, attributed to financing leasing activities by its subsidiary[44] - The company is planning to divest assets related to its metal products business, with the first tranche of transfer payments amounting to 403.73 million yuan made on August 14, 2017[31] Subsidiaries and Operations - The company has established a wholly-owned subsidiary, Hengli New Materials, during the reporting period[55] - The company operates under a make-to-order production model, primarily selling through direct sales in 16 provinces and cities across China[27] - The company has established a comprehensive R&D system for stem cell technology, with services provided across 15 provinces in China[30] - The active carbon production subsidiary, Huahui, is recognized as one of the largest producers in China, holding 17 patents, including 3 invention patents[28] Compliance and Governance - The company emphasizes compliance with relevant laws and regulations in its transactions with related parties[64] - The company has committed to avoiding illegal occupation of funds and assets from related parties[64] - The company guarantees that the assets being sold are free from any new pledges or encumbrances until the relevant transaction agreements are fully executed[66] - The company has established procedures for decision-making in related transactions to ensure transparency[64] Market and Industry Conditions - The domestic steel wire rope industry faces a structural shortage of high-tech, high-value-added products, while the market is oversaturated with low-tech products[27] - The prestressed steel strand industry is characterized by seasonal demand, with winter being the off-peak season[27] - The company faces risks in the metal products industry due to intense competition and price volatility of raw materials, which may impact production and performance[56] Research and Development - The company’s R&D expenditure increased by 237.28% to CNY 10,577.09 million, primarily due to increased spending in its subsidiary, Boya Stem Cells[41] - The company has developed a series of high-tech active carbon products, enhancing its competitive edge in the market[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 28,840[90] - The top shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 200,000,000 shares, representing 29.20% of the total shares[91] - Beijing Zhengneng Weiye Investment Co., Ltd. owns 125,000,000 shares, accounting for 18.25% of the total shares[91] Financial Reporting and Accounting - The company adheres to the accounting standards, ensuring that the financial statements accurately reflect its financial position and operating results[151] - The company has implemented specific accounting treatments for mergers and acquisitions, including the recognition of goodwill and fair value adjustments[155] - The company recognizes revenue and expenses based on its accounting policies, ensuring consistency across its subsidiaries[156]
宁科生物(600165) - 2016 Q4 - 年度财报
2017-05-25 16:00
Financial Performance - The company's operating revenue for 2016 was CNY 2,785,053,869.73, an increase of 158.68% compared to CNY 1,076,651,547.45 in 2015[22] - The net profit attributable to shareholders for 2016 was a loss of CNY 192,020,695.40, a decrease of 516.63% from a profit of CNY 46,088,660.78 in 2015[22] - The company's total assets decreased by 14.70% to CNY 3,345,941,916.75 at the end of 2016, down from CNY 3,922,652,843.69 in 2015[22] - The net asset attributable to shareholders decreased by 17.30% to CNY 796,752,248.80 at the end of 2016, compared to CNY 963,408,720.36 at the end of 2015[22] - The basic earnings per share for 2016 was -CNY 0.280, a decrease of 517.91% from CNY 0.067 in 2015[23] - The weighted average return on equity for 2016 was -21.885%, a decrease of 26.77 percentage points from 4.887% in 2015[23] - The company reported a net cash flow from operating activities of -CNY 191,051,016.96 for 2016, an improvement from -CNY 234,800,343.97 in 2015[22] - The company reported a net profit attributable to shareholders of CNY -19,202.07 million for the year[43] - The company reported a net loss of CNY 234,471,764.06, compared to a loss of CNY 42,451,068.66 in the previous period[171] - The comprehensive income for the period is a loss of CNY 187,799,601.67, reflecting a significant decline in profitability[194] Revenue and Costs - The significant increase in operating revenue was primarily attributed to the increase in copper trading by the subsidiary Hengli International Trade[23] - The company reported total operating costs amounted to ¥3,905,016,719.15, up 223.5% from ¥1,209,389,103.92 in 2015[177] - The company’s revenue from electrolytic copper trading increased by 812.37%, with costs rising by 821.10%, primarily due to increased trading activities by its subsidiary Hengli International Trade[49] - Total revenue from domestic operations reached approximately CNY 2.71 billion, reflecting a year-on-year increase of 170.83%, while foreign revenue decreased by 11.80% to approximately CNY 61.17 million[49] Investment and R&D - The company’s R&D expenditure increased by 941.55% to CNY 22,424.60 million, reflecting a strong commitment to innovation[45] - Research and development expenditures totaled CNY 22.42 million, accounting for 0.81% of total revenue, with 40.06% of R&D costs capitalized[57] - The company is investing in R&D with a budget allocation of 5 million for the development of new technologies and products[136] Subsidiaries and Business Segments - The company operates in the metal products sector, being one of the largest manufacturers of steel wire ropes and prestressed concrete steel strands in China[32] - The biotechnology division focuses on stem cell storage technology and has expanded its services to 15 provinces in China, with over 95% of clients opting for private storage[34] - The company operates five established stem cell banks in Wuxi, Beijing, Chongqing, Nanning, and Guangzhou, covering 15 provinces[36] - Boya Stem Cell's net profit increased by 48.71% year-on-year, primarily due to increased production and storage volumes and government subsidies[71] Shareholder and Equity Information - The company did not implement any profit distribution for the year due to a cumulative loss of CNY 214,350,327.13 available for distribution to shareholders[5] - The company did not propose a cash profit distribution plan despite having positive distributable profits for ordinary shareholders[87] - The company has established a three-year shareholder dividend return plan to ensure stable returns while maintaining sustainable development[84] - The company has committed to not engaging in any business that competes with its main operations, ensuring the protection of shareholder interests[88] Risks and Challenges - The company has outlined potential risks in its future development plans, which investors are advised to consider[6] - The company faces risks from fluctuating raw material prices and intense competition in the metal products sector, which may impact operational performance[79] - The government is increasing regulatory oversight in the stem cell industry, which may affect the approval process for new treatments and technologies[80] Corporate Governance and Compliance - The company has established a comprehensive internal control management system to prevent risks and ensure compliance with laws and regulations[150] - The company received a standard unqualified audit opinion for its financial statements for the year ending December 31, 2016, affirming that they fairly represent the company's financial position[167] - The audit committee conducted a thorough review of the 2015 financial report, ensuring compliance with auditing standards and recommending the reappointment of the auditing firm for 2016[157] Employee and Workforce Information - The total number of employees in the parent company is 1,418, and in major subsidiaries, it is 993, resulting in a total of 2,411 employees[143] - The professional composition includes 1,753 production personnel, 335 sales personnel, 90 technical personnel, 48 financial personnel, and 185 administrative personnel[143] - The company has implemented targeted training programs for 91 wire drawing workers, 140 rope workers, and 268 safety personnel to enhance quality awareness and operational skills[144] Future Outlook and Strategic Plans - The company aims for a consolidated revenue of 1.26 billion RMB and a metal product sales volume of 160,000 tons for the year 2017[77] - Future outlook suggests a projected revenue growth of 20% for the upcoming fiscal year, driven by new product launches and market expansion strategies[136] - The company plans to focus on new product development and market expansion strategies to improve future performance[176] Financial Management and Guarantees - The total guarantee amount (including guarantees to subsidiaries) is 36,399.40 million RMB, accounting for 46.48% of the company's net assets[103] - The company has no overdue guarantees and no violations reported[104] - The company has entrusted others for cash asset management, indicating active financial management strategies[106]
宁科生物(600165) - 2017 Q1 - 季度财报
2017-04-28 16:00
Financial Performance - Net profit attributable to shareholders was CNY 1,583,834.01, compared to a net loss of CNY 20,106,206.17 in the same period last year[6]. - Operating revenue decreased by 62.97% to CNY 236,721,837.66 from CNY 639,301,901.39 year-on-year[6]. - The weighted average return on net assets was 0.199%, up from -0.021% in the same period last year[6]. - Operating revenue decreased to ¥236,721,837.66, down 62.97% from ¥639,301,901.39 in the same period last year[12]. - Investment income decreased by 46.75% to ¥6,088,696.73, due to reduced earnings from associated companies[12]. - The company reported an operating profit of ¥1,695,003.84, a significant improvement from an operating loss of ¥18,669,099.18 in the previous year[29]. - The net profit for Q1 2017 was ¥3,939,295.95, compared to a net loss of ¥19,158,310.66 in the previous year[29]. - The total comprehensive income attributable to the parent company was ¥1,583,834.01, compared to -¥20,106,206.17 in the previous year[32]. Cash Flow - The net cash flow from operating activities was CNY 7,257,742.97, a significant recovery from a negative cash flow of CNY -32,690,687.06 in the previous year[6]. - Net cash flow from operating activities improved to ¥7,257,742.97, a 122.20% increase from a negative ¥32,690,687.06[15]. - Operating cash flow net amount for Q1 2017 was ¥45,132,772.50, a significant improvement from a negative cash flow of ¥29,214,579.96 in the same period last year[42]. - Total cash inflow from operating activities reached ¥231,039,884.27, compared to ¥102,876,961.02 in Q1 2016, marking an increase of approximately 125%[42]. - Cash outflow from operating activities was ¥185,907,111.77, up from ¥132,091,540.98 year-over-year, indicating a rise of about 41%[42]. - The company reported a cash outflow of ¥13,307,574.50 related to other operating activities, down from ¥38,609,318.34 year-over-year, indicating a decrease of about 65%[42]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,353,908,809.72, a 0.24% increase from the previous year-end[6]. - The company’s total assets amounted to ¥3,353,908,809.72, slightly up from ¥3,345,941,916.75[21]. - Total liabilities increased to ¥2,144,178,876.54 from ¥2,142,772,598.62 at the start of the year[26]. - The company's equity attributable to shareholders was ¥779,881,253.32, down from ¥783,179,314.00 at the beginning of the year[26]. - Cash and cash equivalents decreased to ¥157,433,477.23 from ¥219,286,959.69 at the beginning of the year, a decline of 28.23%[25]. - Inventory increased to ¥243,586,586.96, up 24.87% from ¥194,953,854.38 at the beginning of the year[25]. - Short-term borrowings rose to ¥627,000,000.00 from ¥623,000,000.00, indicating a slight increase[26]. Shareholder Information - The number of shareholders at the end of the reporting period was 27,828[8]. - The top shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., held 200,000,000 shares, accounting for 29.20% of total shares[9]. Operational Changes - The company reported an increase in accounts receivable due to received payments for goods sold[11]. - Prepaid accounts increased due to higher advance payments made by a subsidiary for goods[11]. - The company is investing in technology upgrades at its subsidiary, Ningxia Huahui Activated Carbon Co., Ltd., leading to an increase in construction in progress[11]. - Sales expenses increased by 44.04% to ¥30,213,440.72, attributed to higher sales costs from subsidiaries[13]. - The company incurred sales expenses of ¥10,263,566.26, up from ¥5,978,580.48 in the previous year, reflecting increased marketing efforts[35]. Investment Activities - The company’s subsidiary, Ningxia Huahui Activated Carbon Co., Ltd., received approval for listing on the National Equities Exchange and Quotations[17]. - The company did not report any cash inflow from investment activities, with a net cash flow from investment activities of -¥2,915,552.15, consistent with the previous year[42].
宁科生物(600165) - 2016 Q3 - 季度财报
2016-10-28 16:00
Financial Performance - Operating revenue for the first nine months was CNY 2,505,138,771.48, a significant increase of 288.75% compared to CNY 644,416,538.52 in the same period last year[5]. - Net profit attributable to shareholders was a loss of CNY 81,459,078.65, compared to a loss of CNY 17,336,260.46 in the previous year[5]. - The weighted average return on net assets was -8.81%, compared to -1.90% in the previous year[5]. - Total operating revenue for Q3 2016 reached ¥911,741,513.88, a significant increase from ¥262,360,054.54 in Q3 2015, representing a growth of approximately 247%[31]. - Total operating costs for the first nine months of 2016 were ¥2,608,818,706.47, up from ¥759,178,147.34 in the same period last year, indicating an increase of about 243%[31]. - The net loss for Q3 2016 was ¥25,631,388.12, compared to a net profit of ¥41,088,282.87 in Q3 2015, marking a decline of approximately 162%[32]. - The company reported a total profit loss of ¥22,530,820.42 in Q3 2016, contrasting with a profit of ¥41,902,645.14 in Q3 2015, reflecting a decrease of around 153%[32]. - Basic earnings per share for Q3 2016 were -¥0.041, down from ¥0.149 in Q3 2015, indicating a decline of approximately 127%[33]. - Operating profit for the first nine months of 2016 was -¥96,601,180.31, compared to a profit of ¥6,206,632.38 in the same period last year, representing a decrease of about 1,554%[35]. - Investment income for Q3 2016 was ¥7,518,793.81, a decrease from ¥75,679,502.42 in Q3 2015, indicating a decline of approximately 90%[31]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 4,013,422,683.50, an increase of 2.31% compared to the end of the previous year[5]. - Total liabilities rose to CNY 3,014,575,478.07 from CNY 2,890,438,452.86, indicating an increase of about 4.3%[25]. - Current liabilities totaled CNY 1,815,703,702.51, up from CNY 1,691,912,720.50, reflecting a growth of approximately 7.3%[24]. - Total equity decreased to CNY 998,847,205.43 from CNY 1,032,214,390.83, a decline of approximately 3.2%[25]. - Cash and cash equivalents increased to CNY 176,976,823.44 from CNY 89,046,906.62, a significant rise of about 98.7%[27]. - Accounts receivable decreased to CNY 166,120,482.83 from CNY 175,086,201.96, a decline of approximately 5.5%[27]. - Inventory decreased slightly to CNY 239,115,922.80 from CNY 244,294,307.72, a reduction of about 2.1%[27]. - Total current assets reached CNY 650,311,754.76, an increase from CNY 577,955,458.53, reflecting a growth of about 12.5%[27]. Cash Flow - The net cash flow from operating activities for the first nine months was CNY 128,102,281.22, down 32.01% from CNY 188,400,840.13 in the same period last year[5]. - The company reported a net cash inflow from financing activities of CNY 182,408,422.67, compared to CNY 46,839,524.64 in the previous year, showing an increase of approximately 288%[39]. - Cash and cash equivalents at the end of the reporting period totaled CNY 338,933,631.77, up from CNY 230,402,876.59 at the same time last year, reflecting a growth of about 47%[39]. - The company invested CNY 124,000,000.00 in new projects during the first nine months, compared to CNY 232,708,580.00 in the same period last year, indicating a decrease of approximately 47%[39]. - Cash inflow from investment activities was CNY 106,809,273.95, down from CNY 197,002,155.27 year-over-year, indicating a decline of approximately 46%[39]. - The company reported a net cash outflow from investment activities of CNY -23,665,367.85, compared to CNY -64,483,049.89 in the previous year, showing an improvement of about 63%[39]. Shareholder Information - The number of shareholders at the end of the reporting period was 30,130[6]. - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., held 200,000,000 shares, accounting for 29.20% of total shares[6]. Government Support and Non-Operating Income - The company received government subsidies amounting to CNY 4,350,677.35 for the first nine months, which are closely related to its normal business operations[6]. - The company reported a total of CNY 931,872.81 in non-operating income for the third quarter[6]. Corporate Governance - The company has committed to not engaging in competitive businesses with its main operations, ensuring no conflicts of interest arise[20]. - The company has taken measures to prevent its subsidiaries from competing with its main business, reinforcing its commitment to corporate governance[20]. - The company has pledged to prioritize business opportunities that may conflict with its main operations, ensuring transparency and fairness in its dealings[20].
宁科生物(600165) - 2016 Q2 - 季度财报(更新)
2016-09-07 16:00
Financial Performance - The company's operating revenue for the first half of 2016 was approximately RMB 1.59 billion, representing a 317.06% increase compared to the same period last year[24]. - The net profit attributable to shareholders of the listed company was a loss of approximately RMB 53.42 million, an improvement from a loss of RMB 58.22 million in the same period last year[24]. - The net cash flow from operating activities was negative RMB 41.93 million, a decrease of 132.26% compared to a positive cash flow of RMB 129.98 million in the previous year[24]. - The total assets at the end of the reporting period were approximately RMB 4.06 billion, an increase of 3.50% from the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 6.04% to approximately RMB 905.23 million compared to the end of the previous year[24]. - The basic earnings per share for the first half of 2016 was -0.078 yuan, compared to -0.213 yuan in the same period last year[24]. - The diluted earnings per share for the first half of 2016 was also -0.078 yuan, consistent with the basic earnings per share[24]. - The weighted average return on net assets was -5.707%, an improvement from -6.529% in the same period last year[24]. Revenue Breakdown - The company achieved operating revenue of CNY 1,593.40 million, a significant increase of 317.06% compared to the previous year[30]. - The company’s subsidiary, Guomao Company, engaged in copper trading, generating revenue of CNY 1,235.60 million, contributing to the overall revenue growth[30]. - Domestic revenue reached CNY 1,557.32 million, up 334.86% from the previous year, driven by increased trade activities[39]. - The company’s foreign revenue was CNY 31.67 million, representing a growth of 57.50% year-on-year[39]. Research and Development - Research and development expenses increased by 109.05% to CNY 3.14 million, reflecting the company's commitment to innovation[33]. - The company has developed over ten core technologies in metal products, including pre-tensioning technology and optimized design for steel wire rope, filling domestic gaps and achieving breakthroughs in large-tonnage pre-tensioning technology[41]. - The company holds 5 utility model patents and has registered software copyrights for logistics management systems related to steel wire rope production[41]. Investments and Subsidiaries - The company holds a 9.55% stake in Huanghe Bank, resulting in an investment income of CNY 19.62 million during the reporting period[33]. - By the end of the reporting period, the company had established 5 stem cell banks across major cities in China, covering 12 provinces and planning further expansion[42]. - The company completed the acquisition of a 30% stake in Jiangsu Boya Stem Cell Technology Co., Ltd. on May 12, 2016[54]. - The company has five subsidiaries, including Ningxia Hengli Coal Industry Co., Ltd. and Boya Stem Cell Technology Co., Ltd.[118]. Shareholder Information - The total number of shareholders reached 31,536 by the end of the reporting period[71]. - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. held 200,000,000 shares, accounting for 29.20% of total shares[72]. - Beijing Zhengneng Weiye Investment Co., Ltd. held 125,000,000 shares, representing 18.25% of total shares[72]. - The company experienced no changes in controlling shareholders or actual controllers during the reporting period[74]. Financial Position - Total assets increased to CNY 4,060,129,800.20 from CNY 3,922,652,843.69, representing a growth of approximately 3.5%[85]. - Current assets rose to CNY 1,363,308,619.95, up from CNY 1,207,447,820.62, indicating an increase of about 12.9%[84]. - Total liabilities increased to CNY 3,087,620,599.00 from CNY 2,890,438,452.86, reflecting a rise of approximately 6.8%[86]. - The total owner's equity decreased to CNY 972,509,201.20 from CNY 1,032,214,390.83, a decline of approximately 5.8%[86]. Cash Flow Analysis - The company's cash flow from operating activities was negative at -41,927,809.82 RMB, compared to a positive 129,981,731.56 RMB in the same period last year[98]. - Total cash inflow from operating activities was 2,098,716,584.65 RMB, while cash outflow was 2,140,644,394.47 RMB, resulting in a net cash flow from operating activities of -41,927,809.82 RMB[98]. - The net cash flow from investing activities was -4,620,315.83 RMB, a significant improvement from -241,714,632.98 RMB in the previous year[99]. - Cash inflow from financing activities totaled 642,389,166.99 RMB, while cash outflow was 533,748,211.46 RMB, leading to a net cash flow from financing activities of 108,640,955.53 RMB[99]. Accounting Policies - The company has not changed its accounting policies or estimates during the reporting period[65]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect the company's financial status and operating results[123]. - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, with the loss measured as the difference between the asset's carrying amount and the present value of expected future cash flows[140]. Risk Management - The company has not adopted the percentage of receivables method for bad debt provision, indicating a conservative approach to credit risk management[200]. - The provision for bad debts reflects a cautious approach, with higher provisions for older receivables, particularly those over 5 years old, which are fully provided for at 100%[200].
宁科生物(600165) - 2016 Q2 - 季度财报
2016-08-30 16:00
Financial Performance - The company's operating revenue for the first half of 2016 was CNY 1,593,397,257.60, representing a 317.06% increase compared to CNY 382,056,483.98 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was a loss of CNY 53,421,339.49, an improvement from a loss of CNY 58,218,083.29 in the previous year[24]. - The net cash flow from operating activities was negative CNY 41,927,809.82, a decrease of 132.26% compared to a positive cash flow of CNY 129,981,731.56 in the same period last year[24]. - The total assets at the end of the reporting period were CNY 4,060,129,800.20, an increase of 3.50% from CNY 3,922,652,843.69 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 6.04% to CNY 905,233,575.70 from CNY 963,408,720.36 at the end of the previous year[24]. - Basic earnings per share for the first half of 2016 were CNY -0.078, compared to CNY -0.213 in the same period last year[24]. - The weighted average return on net assets was -5.707%, an improvement from -6.529% in the previous year[24]. - The company achieved operating revenue of CNY 1,593.40 million, a significant increase of 317.06% compared to the previous year[30]. - The net profit attributable to shareholders was CNY -53.42 million, indicating a loss during the reporting period[30]. - The company reported a net cash flow from operating activities of CNY -41.93 million, a decline of 132.26% year-on-year[33]. - The company reported a significant increase in prepayments to CNY 131,672,784.99 from CNY 42,164,822.34, representing a growth of about 212.5%[84]. - The company reported a comprehensive income of 58,955,292.59 for the current period, contributing positively to the overall equity[111]. Revenue and Sales - Domestic revenue reached CNY 1,557.32 million, up 334.86% from the previous year, driven by increased trade activities[39]. - The company’s subsidiary, Guomao Company, engaged in copper trading, generating revenue of CNY 1,235.60 million, contributing to the overall revenue growth[30]. - The company’s metal products sales volume was 55,400 tons, achieving 42.62% of the annual target of 130,000 tons[35]. - Sales revenue from goods and services received was 2,033,228,366.47 RMB, a substantial increase from 573,337,032.81 RMB in the previous period[98]. Investments and Assets - The company holds a 9.55% stake in Huanghe Bank, resulting in an investment income of CNY 19.62 million during the reporting period[33]. - The company holds a 9.55% stake in Huanghe Bank, with a book value of approximately CNY 464.68 million and recognized investment income of CNY 19.62 million during the reporting period[44]. - Huanghe Bank reported a net profit of CNY 202.40 million for the reporting period, contributing to the company's investment income[44]. - The company's long-term equity investments stood at CNY 464,683,053.22, a marginal increase from CNY 461,684,688.76[84]. - The total amount of other receivables at the end of the period is CNY 25,066,145.80, with a bad debt provision of CNY 1,759,688.46, representing 7.02% of the total[200]. Research and Development - R&D expenses increased by 109.05% to CNY 3.14 million, reflecting the company's commitment to innovation[33]. - The company has developed over ten core technologies in metal products, including pre-tensioning technology and optimized design for steel wire rope, filling domestic gaps and achieving breakthroughs in large-tonnage pre-tensioning technology[41]. - The company holds 5 utility model patents and has registered software copyrights for logistics management systems related to steel wire rope production[41]. Corporate Governance and Structure - The company did not implement any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[6]. - There were no non-operating fund occupation situations by controlling shareholders and their related parties[8]. - The company has approved related party transactions, including sales of electrolytic copper and bank acceptance bills[53]. - The company completed the acquisition of a 30% stake in Jiangsu Boya Stem Cell Technology Co., Ltd.[54]. - The total number of shareholders reached 31,536 by the end of the reporting period[71]. - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. holds 200,000,000 shares, accounting for 29.20% of total shares[72]. - The company experienced no changes in controlling shareholders or actual controllers during the reporting period[74]. - Four independent directors resigned after completing their six-year terms, while four new independent directors were appointed[79]. Financial Position and Liabilities - The company's total liabilities reached CNY 3,087,620,599.00, compared to CNY 2,890,438,452.86, marking an increase of around 6.8%[86]. - The total owner's equity decreased to CNY 972,509,201.20 from CNY 1,032,214,390.83, a decline of approximately 5.8%[86]. - The total guarantee amount (including guarantees to subsidiaries) is 37,599.40 million, accounting for 40.77% of the company's net assets[58]. - The total guarantee amount to subsidiaries during the reporting period is 22,329.40 million, with a year-end balance of 23,399.40 million[58]. - The company has multiple guarantees with amounts ranging from 125 million RMB to 2,500 million RMB, all set to expire in 2016[57]. Accounting Policies and Compliance - The company has not changed its accounting policies or estimates during the reporting period[65]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements reflect the true financial condition and operating results[123]. - The company’s accounting policies and estimates are based on actual transactions and events, ensuring compliance with relevant regulations[121]. - The company recognizes liabilities for retirement benefits and severance payments based on obligations incurred, with severance payments discounted if payable beyond one year[165]. Future Outlook and Risks - The report includes a risk statement regarding forward-looking statements, indicating that future plans and strategies do not constitute a substantive commitment to investors[7]. - The company anticipates a significant change in cumulative net profit compared to the same period last year[51]. - There are no warnings regarding potential losses or significant changes in net profit for the upcoming reporting period[51]. - Future outlook and guidance were not explicitly mentioned, suggesting a potential area for further clarification in upcoming communications[97].
宁科生物(600165) - 2015 Q4 - 年度财报
2016-05-13 16:00
Financial Performance - In 2015, the company's operating revenue was CNY 1,076,651,547.45, a decrease of 19.84% compared to CNY 1,343,165,677.31 in 2014[20] - The net profit attributable to shareholders was CNY 46,088,660.78, a significant recovery from a loss of CNY 107,963,614.24 in 2014[20] - The basic earnings per share for 2015 was CNY 0.067, recovering from a loss of CNY 0.394 in 2014[21] - The company reported a net profit attributable to shareholders of RMB 46,088,660.78 for the year 2015, a significant recovery from a loss of RMB 107,963,614.24 in 2014[82] - The net profit for 2015 was CNY 47,165,215.71, a significant recovery from a net loss of CNY 114,082,334.80 in the previous year[185] Assets and Liabilities - The company's total assets increased by 63.39% to CNY 3,922,652,843.69 at the end of 2015, compared to CNY 2,400,794,698.54 at the end of 2014[20] - The total liabilities increased to CNY 2,507,302,492.33, up from CNY 1,024,120,158.39, indicating a rise of approximately 144.5%[182] - The total equity attributable to shareholders was CNY 963,408,720.36, compared to CNY 920,783,885.27 at the beginning of the year, reflecting a modest increase of approximately 4.6%[179] - The company's total liabilities reached CNY 2,890,438,452.86, up from CNY 1,476,468,804.51, indicating a significant increase of about 96.5%[178][179] Cash Flow - The net cash flow from operating activities was CNY -234,800,343.97, slightly improved from CNY -241,897,813.04 in 2014[20] - The company experienced a net cash flow from operating activities of RMB 152,781,832.94 in the first quarter, but faced a negative cash flow of RMB -423,201,184.10 in the fourth quarter, indicating volatility in cash management[24] - Cash flow from operating activities showed a net outflow of ¥234,800,343.97, slightly improved from a net outflow of ¥241,897,813.04 in the previous year[192] Investments and Acquisitions - The company sold 100% equity and debt of its subsidiary Shanghai Zhongshang Industrial Co., Ltd., and acquired 80% equity of Boya Stem Cell[35] - The company’s investment activities generated a net cash outflow of CNY 997,665,594.46, primarily due to the acquisition of Boya Stem Cell[43] - The company has acquired 80% of Boya Stem Cells, transitioning to a dual-main business model in metal products and biotechnology[74] Market Position and Strategy - The company is one of the largest manufacturers of steel wire ropes in China, with over 70 product varieties and 1,500 specifications, maintaining a leading position in the domestic market[30] - The domestic steel wire rope industry is characterized by an oversupply of low-tech products, while high-tech, high-value products remain in short supply, indicating a market opportunity for the company[31] - The company plans to enhance production efficiency and increase the sales proportion of high-value-added products to maintain competitive advantages in the steel wire rope industry[71] - The company plans to focus on expanding its market presence and enhancing product development strategies moving forward[189] Research and Development - The company’s R&D expenditure decreased by 32% to CNY 2,153,006.34, indicating reduced investment in innovation[42] - R&D investment totaled ¥8.874 million, with 12 technology projects implemented[55] - The company plans to enhance its research and development capabilities and explore new investment areas to seek further growth[75] Governance and Compliance - The company has committed to fair and reasonable transactions with related parties, adhering to market principles[84] - The company has ensured compliance with legal and regulatory requirements in its operations and transactions, safeguarding its reputation[85] - The company has established a system for managing insider information to prevent insider trading and ensure fair information disclosure[153] Shareholder Information - The company has implemented a cash dividend policy to ensure stable returns for investors while maintaining sustainable development[80] - The company did not implement a profit distribution for 2015 due to a cumulative profit available for distribution of CNY -14,104,891.94[5] - The total number of shareholders at the end of the reporting period was 30,524, down from 34,030 at the end of the previous month[119] Employee and Management - The total number of employees in the parent company is 1,922, while the total number of employees in major subsidiaries is 1,041, resulting in a combined total of 2,963 employees[146] - The total compensation for senior management at the end of the reporting period amounted to 3.111 million yuan[143] - The company has implemented a performance-based salary system for senior management, combining a basic annual salary with a performance bonus[143] Risks and Challenges - The company faced significant risks as detailed in the board report, which investors are advised to review[6] - The company faces risks from intense competition in the metal products industry and fluctuating raw material prices affecting production costs[76] - The stem cell industry is experiencing increased regulatory scrutiny, which may impact the approval of clinical applications and treatments[77]
宁科生物(600165) - 2016 Q1 - 季度财报
2016-04-29 16:00
Financial Performance - Operating revenue surged by 284.76% to CNY 639,301,901.39 year-on-year[6] - Net profit attributable to shareholders was a loss of CNY 20,106,206.17, an improvement from a loss of CNY 32,307,506.76 in the same period last year[6] - Operating revenue increased to $639.30 million, up 284.76% from $166.15 million in the same period last year[13] - The net loss for Q1 2016 was ¥19,158,310.66, compared to a net loss of ¥32,299,735.42 in Q1 2015, showing an improvement of approximately 40.6%[34] - The company reported an operating profit of -¥18,669,099.18 for Q1 2016, an improvement from -¥34,910,419.21 in Q1 2015[34] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY 32,690,687.06, a decline of 121.40% compared to the previous year[6] - Net cash flow from operating activities decreased to -$32.69 million, a decline of 121.40% compared to $152.78 million in the previous year[15] - The cash flow from operating activities shows a net outflow of -¥32,690,687.06, compared to a net inflow of ¥152,781,832.94 in the previous period[41] - Operating cash flow for Q1 2016 was negative at -29,214,579.96 RMB, a significant decrease from 137,716,240.88 RMB in the same period last year, reflecting a decline of approximately 121%[44] - The company’s cash flow from investment activities was negative at -2,494,545.79 RMB, compared to -231,823,610.43 RMB in the same period last year, showing an improvement of approximately 99%[44] Assets and Liabilities - Total assets increased by 5.20% to CNY 4,126,798,544.70 compared to the end of the previous year[6] - The company's current assets totaled CNY 1,414,239,843.33, up from CNY 1,207,447,820.62 at the start of the year, reflecting a growth of approximately 17.1%[24] - The total liabilities reached CNY 3,117,628,630.24, compared to CNY 2,890,438,452.86 at the beginning of the year, indicating an increase of approximately 7.9%[26] - The company's short-term borrowings rose to CNY 1,099,780,000.00 from CNY 914,760,000.00, marking an increase of about 20.2%[25] - The company's total liabilities increased to ¥2,606,998,816.94 from ¥2,507,302,492.33, marking a rise of approximately 4.0%[29] Shareholder Information - The number of shareholders reached 34,030, with the top ten shareholders holding a combined 78.12% of shares[9] - The company has committed to not engaging in competitive business activities with its main operations and ensuring the protection of minority shareholders' interests[19] Operational Costs - Operating costs rose to $607.27 million, reflecting a 295.36% increase from $153.60 million year-over-year[13] - Sales expenses increased to $20.98 million, a rise of 56.26% from $13.42 million year-over-year, primarily due to the consolidation of Boya Stem Cell Technology Co., Ltd.[14] - Management expenses rose to $16.98 million, an 18.00% increase from $14.39 million, also attributed to the consolidation of Boya Stem Cell Technology Co., Ltd.[14] Other Financial Metrics - The weighted average return on net assets was -0.021%, an improvement from -3.571% in the previous year[6] - The company recorded a total of CNY 414,408.44 in non-recurring gains and losses during the reporting period[7] - The company has not indicated any significant changes in its net profit forecast for the year compared to the previous year[21] - Basic and diluted earnings per share for Q1 2016 were both -¥0.029, compared to -¥0.118 in the same quarter last year, indicating a reduction in loss per share[35]
宁科生物(600165) - 2015 Q3 - 季度财报
2015-10-08 16:00
Financial Performance - Operating income decreased by 44.21% to CNY 644,416,538.52 for the first nine months compared to the same period last year[7] - Net profit attributable to shareholders was CNY -17,336,260.46, showing a significant decline from CNY -6,595,482.32 in the previous year[7] - Operating revenue decreased to ¥644,416,538.52, down 44.21% from ¥1,154,997,326.90 in the same period last year[14] - Total revenue for the third quarter was CNY 262,360,054.54, a decrease of 37.9% compared to CNY 422,594,010.02 in the same period last year[34] - The company's net profit for the first nine months was CNY 93,687,114.86, compared to CNY 86,741,881.48 in the same period last year, reflecting a year-over-year increase of 8.5%[34] - Net profit for Q3 2015 reached ¥50,574,265.10, compared to a net loss of ¥19,819,125.89 in Q3 2014[40] - Total profit for Q3 2015 was ¥50,574,265.10, significantly improving from a loss of ¥23,316,618.69 in the same period last year[39] Cash Flow - Net cash flow from operating activities increased by 252.52% to CNY 188,400,840.13 for the first nine months compared to the same period last year[7] - Operating cash flow for the period from January to September reached ¥188,400,840.13, a significant increase from ¥53,444,742.40 in the same period last year, representing a growth of approximately 252.5%[43] - Total cash inflow from operating activities was ¥1,009,361,220.16, compared to ¥1,559,811,939.48 in the previous year, indicating a decrease of about 35.2%[43] - Cash outflow from operating activities totaled ¥820,960,380.03, down from ¥1,506,367,197.08 year-on-year, a reduction of approximately 45.5%[43] - Net cash flow from investing activities decreased to -¥64,483,049.89, a decline of 190.70% compared to -¥22,181,746.47 last year[16] - The net cash flow from financing activities was ¥46,839,524.64, a turnaround from -¥42,953,705.97 in the same period last year[44] Assets and Liabilities - Total assets increased by 5.42% to CNY 2,530,852,913.63 compared to the end of the previous year[7] - The company's total liabilities reached CNY 1,599,204,918.45, compared to CNY 1,476,468,804.51 at the beginning of the year, marking an increase of about 8.3%[27] - Short-term borrowings increased due to increased bank loans and reclassification of discounted notes[12] - The company's current assets totaled CNY 1,406,022,084.08, up from CNY 1,127,230,025.26 at the beginning of the year, indicating a significant increase of about 24.7%[25] - The company's total equity amounted to CNY 931,647,995.18, slightly up from CNY 924,325,894.03, showing a marginal increase of about 0.3%[27] Shareholder Information - The number of shareholders reached 10,412 at the end of the reporting period[10] - The company reported a significant increase in minority shareholders' equity, which rose to ¥32,520,119.14, up 818.13% from ¥3,542,008.76[14] Investments and Subsidiaries - The company completed the sale of its wholly-owned subsidiary Shanghai Zhongzheng Industrial Co., Ltd. for ¥196,187,012.46, generating an investment income of ¥77,081,400.00[20] - The company plans to increase its stake in Ningxia Huahui Activated Carbon Co., Ltd. by up to 6,304 million shares, currently holding 60.21%[17] Inventory and Receivables - The company's inventory stood at CNY 407,213,890.65, up from CNY 385,969,185.42, which is an increase of about 5.3%[25] - Accounts receivable increased to CNY 376,667,720.18 from CNY 337,841,475.95, representing a growth of approximately 11.5%[25]
宁科生物(600165) - 2015 Q2 - 季度财报
2015-08-28 16:00
Financial Performance - The company's operating revenue for the first half of 2015 was ¥382,056,483.98, a decrease of 47.84% compared to ¥732,403,316.88 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥58,218,083.29, representing a decline of 457.60% from a profit of ¥16,280,171.89 in the previous year[21]. - Basic earnings per share for the first half of 2015 were -¥0.213, a decrease of 461.02% compared to ¥0.059 in the same period last year[22]. - The weighted average return on net assets was -6.529%, a decrease of 8.086 percentage points from 1.557% in the previous year[22]. - The company reported a significant decline in sales volume and prices due to the sluggish coal and steel industries, impacting overall revenue[28]. - The company reported a net loss of ¥146,757,812.73 compared to a loss of ¥88,539,729.44 in the previous period[80]. - The comprehensive income for the current period is a loss of CNY 58,412,088.94, indicating a significant decline in profitability[99]. - The total equity at the end of the current period is CNY 881,918,265.14, down from 924,044,008.97 at the end of the previous period, reflecting a decrease of 4.56%[103]. Cash Flow - The net cash flow from operating activities increased by 302.16% to ¥129,981,731.56, compared to ¥32,321,283.18 in the same period last year[21]. - Operating cash inflow for the period was CNY 617,974,505.67, down 37.0% from CNY 980,197,023.69 in the previous period[93]. - Cash inflow from sales of goods and services was CNY 573,337,032.81, a decline from CNY 909,443,934.91 in the previous period[93]. - Cash outflow from investment activities totaled CNY 241,924,632.98, significantly higher than CNY 13,309,375.53 in the previous period[94]. - Cash inflow from financing activities was CNY 654,131,000.00, up from CNY 325,100,000.00 in the previous period[94]. - The ending cash and cash equivalents balance decreased to CNY 34,544,216.56 from CNY 117,078,264.15 in the previous period[94]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,484,589,672.04, an increase of 3.49% from ¥2,400,794,698.54 at the end of the previous year[21]. - Total liabilities increased to ¥1,618,971,185.28 from ¥1,476,468,804.51, marking an increase of approximately 9.6%[80]. - Current assets increased to ¥1,241,852,939.99 from ¥1,127,230,025.26, representing a growth of approximately 10.2%[78]. - Total equity attributable to shareholders decreased to ¥862,279,018.34 from ¥920,783,885.27, a decline of approximately 6.3%[80]. Shareholder Information - The company plans to increase its capital reserve by converting every 10 shares into 15 shares, resulting in a total share capital increase to 684,883,775 shares[5]. - The first major shareholder's equity was judicially auctioned, with Shanghai Zhongneng acquiring the company's shares[58]. - The first major shareholder, Shanghai Zhongneng, holds 80 million shares, which are still under lock-up restrictions[64]. - The company guarantees not to harm the interests of minority shareholders during its normal production and operational activities[55]. Governance and Compliance - The company has established a governance structure in compliance with relevant laws and regulations, with no significant discrepancies noted[57]. - The company has committed to not utilizing its controlling position to harm the interests of the company and its minority shareholders[55]. - The financial report indicates that the company is in compliance with auditing requirements, as an audit report is applicable[76]. - The company has not reported any changes in accounting policies or significant errors during the reporting period[58]. Investment and Capital Structure - The investment income decreased by ¥68,730,000 due to the previous year's sale of shares in Lanzhou Bank, which generated an investment income of ¥87,160,000[28]. - The company acquired 703,300 shares of Huanghe Bank, increasing its total holdings to 138,481,513 shares, representing 9.55% of the bank's total equity[39][40]. - The total amount of guarantees provided by the company, including those to subsidiaries, is 53,269,000 RMB, which accounts for 60.37% of the company's net assets[52]. Accounting Policies - The financial statements are prepared in accordance with the relevant accounting standards, with the reporting currency being Renminbi[77]. - The company recognizes the operating results and cash flows of subsidiaries from the beginning of the reporting period in which they are consolidated[118]. - The company follows specific accounting treatments for mergers and acquisitions, including the recognition of goodwill when the acquisition cost exceeds the fair value of identifiable net assets[116]. - The company employs a systematic approach to assess and recognize bad debts, ensuring financial statements reflect accurate receivable values[132]. Inventory and Receivables - The ending balance of inventory is RMB 452,897,158.60, with a decrease of RMB 9,630,939.55 during the period[196]. - The company's accounts receivable at the end of the period amounted to ¥392,775,672.27, with a bad debt provision of ¥29,715,154.29, representing 7.57% of the total[177]. - The total amount of receivable dividends was ¥18,007,612.44 at the end of the period[184].